Related references
Note: Only part of the references are listed.Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial
G. Michael Felker et al.
JAMA CARDIOLOGY (2022)
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies
Roddy Walsh et al.
NATURE REVIEWS CARDIOLOGY (2022)
Mavacamten preserves length-dependent contractility and improves diastolic function in human engineered heart tissue
Lorenzo R. Sewanan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2021)
Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy
Peter O. Awinda et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2021)
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis
Sara Saberi et al.
CIRCULATION (2021)
Synthetic thick filaments: A new avenue for better understanding the myosin super-relaxed state in healthy, diseased, and mavacamten-treated cardiac systems
Sampath K. Gollapudi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
John R. Teerlink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
Chihyuan Chuang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Two Classes of Myosin Inhibitors, Para-nitroblebbistatin and Mavacamten, Stabilize β-Cardiac Myosin in Different Structural and Functional States
Sampath K. Gollapudi et al.
JOURNAL OF MOLECULAR BIOLOGY (2021)
The N terminus of myosin-binding protein C extends toward actin filaments in intact cardiac muscle
Sheema Rahmanseresht et al.
JOURNAL OF GENERAL PHYSIOLOGY (2021)
Truncated titin proteins in dilated cardiomyopathy
Quentin McAfee et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
To lie or not to lie: Super-relaxing with myosins
Suman Nag et al.
ELIFE (2021)
Cardiac myosin super relaxation (SRX): a perspective on fundamental biology, human disease and therapeutics
Manuel Schmid et al.
BIOLOGY OPEN (2021)
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF)
Tor Biering-Sorensen et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF
John R. Teerlink et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Cardiac sarcomere mechanics in health and disease
Claudia Crocini et al.
BIOPHYSICAL REVIEWS (2021)
Reappraising Genes for Dilated Cardiomyopathy Stepping Back to Move Forward
Anjali Tiku Owens et al.
CIRCULATION (2021)
Cardiac myosin-binding protein C interaction with actin is inhibited by compounds identified in a high-throughput fluorescence lifetime screen
Thomas A. Bunch et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Direct detection of the myosin super-relaxed state and interacting-heads motif in solution
Sami Chu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Danicamtiv Enhances Systolic Function and Frank-Starling Behavior at Minimal Diastolic Cost in Engineered Human Myocardium
Shi Shen et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
Rhanderson Cardoso et al.
ECLINICALMEDICINE (2021)
Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations
Alexander J. Sparrow et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2020)
Characterization of the Cardiac Myosin Inhibitor CK-3773274: a Potential Therapeutic Approach for Hypertrophic Cardiomyopathy
James J. Hartman et al.
BIOPHYSICAL JOURNAL (2020)
Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy
Christopher N. Toepfer et al.
CIRCULATION (2020)
Myosin filament-based regulation of the dynamics of contraction in heart muscle
Elisabetta Brunello et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin
Saswata S. Sarkar et al.
SCIENCE ADVANCES (2020)
Study Design and Rationale of EXPLORER-HCM Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Carolyn Y. Ho et al.
CIRCULATION-HEART FAILURE (2020)
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial
Adriaan A. Voors et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy
Carolyn Y. Ho et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Imaging ATP Consumption in Resting Skeletal Muscle: One Molecule at a Time
Shane R. Nelson et al.
BIOPHYSICAL JOURNAL (2020)
Effects of mavacamten on Ca2+sensitivity of contraction as sarcomere length varied in human myocardium
Peter O. Awinda et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Iacopo Olivotto et al.
LANCET (2020)
Distinct hypertrophic cardiomyopathy genotypes result in convergent sarcomeric proteoform profiles revealed by top-down proteomics
Trisha Tucholski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Small Molecules Acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases
Khulud Alsulami et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy
Adam S. Helms et al.
JCI INSIGHT (2020)
Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations
James A. Spudich
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2019)
Revealing the mechanism of how cardiac myosin-binding protein C N-terminal fragments sensitize thin filaments for myosin binding
Alessio V. Inchingolo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin
Christopher N. Toepfer et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy A Clinical Trial
Stephen B. Heitner et al.
ANNALS OF INTERNAL MEDICINE (2019)
Novel Therapies for Prevention and Early Treatment of Cardiomyopathies Now and in the Future
Giuliana G. Repetti et al.
CIRCULATION RESEARCH (2019)
Cardiac myosin binding protein-C phosphorylation regulates the super-relaxed state of myosin
James W. McNamara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin
Mark P. Grillo et al.
XENOBIOTICA (2019)
β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity
Arjun S. Adhikari et al.
NATURE COMMUNICATIONS (2019)
Skeletal MyBP-C isoforms tune the molecular contractility of divergent skeletal muscle systems
Amy Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy
Amelia A. Glazier et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2019)
The Interacting Head Motif Structure Does Not Explain the X-Ray Diffraction Patterns in Relaxed Vertebrate (Bony Fish) Skeletal Muscle and Insect (Lethocerus) Flight Muscle
Carlo Knupp et al.
BIOLOGY-BASEL (2019)
Role of titin in cardiomyopathy: from DNA variants to patient stratification
James S. Ware et al.
NATURE REVIEWS CARDIOLOGY (2018)
Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin
John A. Rohde et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Myosin Head Configurations in Resting and Contracting Murine Skeletal Muscle
Weikang Ma et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Indigenous impacts on North American Great Plains fire regimes of the past millennium
Christopher I. Roos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke
Michael S. Woody et al.
NATURE COMMUNICATIONS (2018)
Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition
Julien Robert-Paganin et al.
NATURE COMMUNICATIONS (2018)
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
Carolyn Y. Ho et al.
CIRCULATION (2018)
Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Veli-Pekka Harjola et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass The LICORN Randomized Clinical Trial
Bernard Cholley et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle
Raja F. Kawas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Omecamtiv Mecarbil Enhances the Duty Ratio of Human -Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle
Anja M. Swenson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Cardiopulmonary Exercise Testing What Is its Value?
Marco Guazzi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Levosimendan for Hemodynamic Support after Cardiac Surgery
G. Landoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery
R. H. Mehta et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phosphorylation of cardiac myosin binding protein C releases myosin heads from the surface of cardiac thick filaments
Robert W. Kensler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Heart failure drug changes the mechanoenzymology of the cardiac myosin powerstroke
John A. Rohde et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
Vicente J. Planelles-Herrero et al.
NATURE COMMUNICATIONS (2017)
Effects of myosin variants on interacting heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes
Lorenzo Alamo et al.
ELIFE (2017)
MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy
James W. McNamara et al.
PLOS ONE (2017)
Dilated Cardiomyopathy Genetic Determinants and Mechanisms
Elizabeth M. McNally et al.
CIRCULATION RESEARCH (2017)
Hypertrophic Cardiomyopathy Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Ali J. Marian et al.
CIRCULATION RESEARCH (2017)
Sarcomere neutralization in inherited cardiomyopathy: small-molecule proof-of-concept to correct hyper-Ca2+-sensitive myofilaments
Brian R. Thompson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2016)
Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes
James W. McNamara et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2016)
Conserved Intramolecular Interactions Maintain Myosin Interacting-Heads Motifs Explaining Tarantula Muscle Super-Relaxed State Structural Basis
Lorenzo Alamo et al.
JOURNAL OF MOLECULAR BIOLOGY (2016)
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
John R. Teerlink et al.
LANCET (2016)
A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice
Eric M. Green et al.
SCIENCE (2016)
A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy
Joshua A. Stern et al.
PLOS ONE (2016)
Omecamtiv Mecarbil Modulates the Kinetic and Motile Properties of Porcine beta-Cardiac Myosin
Yingying Liu et al.
BIOCHEMISTRY (2015)
Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity
Jens Petter Bakkehaug et al.
CIRCULATION-HEART FAILURE (2015)
Cardiovascular Drug Development
Christopher B. Fordyce et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug
Nathan J. Verlinden et al.
PHARMACOTHERAPY (2015)
The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium
Oivind Orstavik et al.
PLOS ONE (2015)
Cardiac MyBP-C Regulates the Rate and Force of Contraction in Mammalian Myocardium
Richard L. Moss et al.
CIRCULATION RESEARCH (2015)
The Myosin Inhibitor Blebbistatin Stabilizes the Super-Relaxed State in Skeletal Muscle
Clyde Wilson et al.
BIOPHYSICAL JOURNAL (2014)
Inotropes and Inodilators for Acute Heart Failure
László Nagy et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Targeting latent TGFβ release in muscular dystrophy
Ermelinda Ceco et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Doubly heterozygous LMNA and TTN mutations revealed by exome sequencing in a severe form of dilated cardiomyopathy
Roberta Roncarati et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2013)
Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure
Milton Packer et al.
JACC-HEART FAILURE (2013)
Surgical treatment of hypertrophic cardiomyopathy
Sameh M. Said et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2013)
Truncations of Titin Causing Dilated Cardiomyopathy
Daniel S. Herman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A New State of Cardiac Myosin with Very Slow ATP Turnover: A Potential Cardioprotective Mechanism in the Heart
Pleuni Hooijman et al.
BIOPHYSICAL JOURNAL (2011)
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
John R. Teerlink et al.
LANCET (2011)
Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Fady I. Malik et al.
SCIENCE (2011)
Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart Failure
You-Tang Shen et al.
CIRCULATION-HEART FAILURE (2010)
The genetics of dilated cardiomyopathy
Lisa Dellefave et al.
CURRENT OPINION IN CARDIOLOGY (2010)
Myosin ATP turnover rate is a mechanism involved in thermogenesis in resting skeletal muscle fibers
Melanie A. Stewart et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin
Bradley P. Morgan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Head-head and head-tail interaction: A general mechanism for switching off myosin II activity in cells
Hyun Suk Jung et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Three-dimensional structure of vertebrate cardiac muscle myosin filaments
Maria E. Zoghbi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Levosimendan vs dobutamine for patients with acute decompensated heart failure - The SURVIVE randomized trial
Alexandre Mebazaa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Atomic model of a myosin filament in the relaxed state
JL Woodhead et al.
NATURE (2005)
The structural basis of blebbistatin inhibition and specificity for myosin II
JS Allingham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2005)
The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig
S Szilágyi et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
The contractile apparatus as a target for drugs against heart failure: Interaction of levosimendan, a calcium sensitiser, with cardiac troponin c
T Sorsa et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2004)
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial
F Follath et al.
LANCET (2002)
Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy
B Gerull et al.
NATURE GENETICS (2002)
Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle
JC Kentish et al.
CIRCULATION RESEARCH (2001)
Binding of levosimendan, a calcium sensitizer, to cardiac troponin C
T Sorsa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy
M Kamisago et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Regulation of contraction in striated muscle
AM Gordon et al.
PHYSIOLOGICAL REVIEWS (2000)
Share Paper
